Navigation Links
Proove Biosciences CEO Brian Meshkin Wins 2013 Bridging the Gap Award by the Greater Baltimore Committee
Date:11/26/2013

Irvine, CA (PRWEB) November 26, 2013

Proove Biosciences, the leading personalized pain medicine laboratory, and CEO, Brian Meshkin, were one of 13 winners of the 2013 Bridging the Gap Awards, an award given to minority-owned and women-owned firms for achievement for their efforts to strengthen business development.

The Greater Baltimore Committee recognized Brian Meshkin and Proove as a leading minority-owned business. The GBC is an organization that aims to improve the business climate of the Greater Baltimore region by organizing corporate and civic leadership to develop strategies that solve problems with the region’s competitiveness and viability.

As stated by the GBC, “Brian Meshkin, son of an immigrant [born in Iran] from Pakistan who, along with his wife Catherine, founded Proove Biosciences, Inc. in the midst of the Great Recession. They developed, among other things, a one-of-a-kind genetic test to identify patients pre-disposed to the risk of pain medication misuse. After a few years dedicated to research and development, the Meshkins put their business model into action and built their Howard County-based firm into a commercial market leader advancing the concept of personalized medicine in pain management.”    

Proove Biosciences President and Founder, Brian Meshkin states, “As members of the greater Baltimore, Maryland and greater Irvine, California communities, we take great pride and honor to be named a recipient of the 2013 Bridging the Gap Award from the GBC. Proove Biosciences was founded with a vision and a mission to change the world. We are proud to demonstrate how to bridge the achievement gap.”

About Proove Biosciences
Proove Biosciences is the leading Personalized Pain Medicine laboratory that provides proprietary genetic testing services to help physicians improve outcomes for patients and contain costs for insurers. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve pain medicine selection, dosing, and evaluation of medications they prescribe. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).

Read the full story at http://www.prweb.com/releases/2013/11/prweb11370517.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Proove Biosciences Will Participate at the California Society of Interventional Pain Physician’s 4th Annual Meeting This Weekend
2. Proove CEO and Vice Chairman of the Howard County Board of Education, Brian Meshkin, Selected as one of Howard County's Finest Under 39 by the Cystic Fibrosis Foundation
3. Proove Biosciences Continues Its Research Leadership in the Genetics of Pain Medicine at The American Academy of Pain Management’s 24th Annual Meeting
4. Proove Biosciences Announces Sponsorship of National Drug Take Back Day and HC DrugFree
5. Proove Biosciences Will Be Exhibiting At The 2013 Common Sense Pain Management Conference
6. Proove Biosciences to Present Research on the Genetics of Pain Medicine and Exhibit at ASRA’s 12th Annual Pain Medicine Meeting
7. Proove Biosciences Will Be Exhibiting at the National Workers Compensation Conference and Expo on November 20-22
8. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
9. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
10. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
11. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , ... December 01, 2016 , ... ... long-term client Nanowear on their recent FDA Class II 510(k) clearance for their ... significant hurdle in commercializing remote cardiac monitoring devices that rely on cloth-based nanosensors. ...
(Date:12/2/2016)... bioLytical Laboratories, a world leader in rapid infectious disease tests, introduced the Company,s newest ... members. (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) Continue Reading ... ... , , bioLytical was invited ... introduce the INSTI HIV Self Test to 350 pharmacy representatives in Nairobi ...
(Date:11/30/2016)... Nov. 30, 2016 Biotest Pharmaceuticals Corporation (BPC), ... to announce the addition of its newest plasma collection ... Nebraska . The 15,200 square foot state-of-the-art facility ... 2016 and brings the total number of BPC,s plasma ... Carlisle , BPC,s Chief Executive Officer said "We are ...
(Date:11/30/2016)... November 2016   Merck , ein ... Unterzeichnung einer Reihe von Vereinbarungen mit Evotec ... AG Screeningleistungen für Mercks Palette genetischer Reagenzien ... auf diese Bibliotheken in Kombination mit Evotecs ... Weg zur Ermittlung und Erforschung neuer Arzneimitteltargets.    ...
Breaking Biology Technology:
(Date:11/29/2016)... CANNES, France , November 29, 2016 Nearly ... Continue Reading ... ... System is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric ...
(Date:11/21/2016)... Nov. 21, 2016   Neurotechnology , a ... technologies, today announced that the MegaMatcher On Card ... submitted for the NIST Minutiae Interoperability Exchange ... the mandatory steps of the evaluation protocol. ... continuing test of fingerprint templates used to establish ...
(Date:11/15/2016)... 2016  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... the gut microbiome, today announced the pricing of ... its common stock and warrants to purchase 50,000,000 ... to the public of $1.00 per share and ... the offering, excluding the proceeds, if any from ...
Breaking Biology News(10 mins):